EN
中文 EN
Company News
Home >Newsroom >Company News
ALL
2025
2024
2023
2022
2021
2020
2019
2018
2016
2015
2014
2013
2012
2007
2018.03.22
National Research Council contribution plays key role in newly approved Ebola vaccine
2016.08.03
CanSino Submits a Clinical Trial Application for the Component DTP Diptheria Tetanus Pertussis Combo Vaccine (Adults, Teenagers and Children Above 6 Years Old)
2016.03.24
World TB Day is March 24. Help us bring an end to the epidemic by supporting TB vaccine research.
2016.02.15
Cansino Biotechnology: Meningococcal Group ACYW135 Quadrivalent Conjugate Vaccine is Approved for Clinical Trial
2016.02.15
Cansino Biotechnology: Meningococcal Group AC Bivalent Conjugate Vaccine, Freeze Dried is Approved for Clinical Trial
2015.10.31
Manufacturing Facility Ground Breaking and Contract-signing Ceremony for Third Round of Financing
2015.03.27
CanSino Biotechnology Successfully Passed EU GMP Audit
2014.12.19
China’s First Ebola Vaccine Approved For Clinical Trials
2014.11.25
CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA
2014.09.16
CanSino awarded “Key Overseas Chinese Entrepreneurial Team
1456789